Beyond Medical Technologies Inc.
DOCT
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.20% | -13.26% | -19.95% | -18.54% | -38.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.20% | -13.26% | -19.95% | -18.54% | -38.32% |
| Operating Income | 21.20% | 13.26% | 19.95% | 18.54% | 38.32% |
| Income Before Tax | 45.15% | 36.95% | 41.33% | 26.20% | 36.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.15% | 36.95% | 41.33% | 26.20% | 36.59% |
| Earnings from Discontinued Operations | 284.23% | 86.94% | 94.40% | 92.56% | 93.49% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.36% | 49.27% | 62.04% | 55.17% | 61.05% |
| EBIT | 21.20% | 13.26% | 19.95% | 18.54% | 38.32% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 62.41% | 49.38% | 62.22% | 55.29% | 61.12% |
| Normalized Basic EPS | 21.36% | 14.83% | 21.12% | 17.36% | 36.67% |
| EPS Diluted | 62.41% | 49.38% | 62.22% | 55.29% | 61.12% |
| Normalized Diluted EPS | 21.36% | 14.83% | 21.12% | 17.36% | 36.67% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |